174 related articles for article (PubMed ID: 25153715)
1. A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.
Luey N; Toon CW; Sioson L; Clarkson A; Watson N; Cussigh C; Kedziora A; Pincott S; Pillinger S; Evans J; Percy J; Engel A; Schnitzler M; Gill AJ
PLoS One; 2014; 9(8):e106105. PubMed ID: 25153715
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.
Toon CW; Walsh MD; Chou A; Capper D; Clarkson A; Sioson L; Clarke S; Mead S; Walters RJ; Clendenning M; Rosty C; Young JP; Win AK; Hopper JL; Crook A; von Deimling A; Jenkins MA; Buchanan DD; Gill AJ
Am J Surg Pathol; 2013 Oct; 37(10):1592-602. PubMed ID: 23797718
[TBL] [Abstract][Full Text] [Related]
3. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.
Toon CW; Chou A; DeSilva K; Chan J; Patterson J; Clarkson A; Sioson L; Jankova L; Gill AJ
Mod Pathol; 2014 May; 27(5):644-50. PubMed ID: 24157612
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
6. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
7. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.
Xia M; Singhi AD; Dudley B; Brand R; Nikiforova M; Pai RK
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):399-406. PubMed ID: 27258561
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
9. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
[TBL] [Abstract][Full Text] [Related]
11. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
[TBL] [Abstract][Full Text] [Related]
12. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
[TBL] [Abstract][Full Text] [Related]
13. Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.
Signoroni S; Tibiletti MG; Ricci MT; Milione M; Perrone F; Pensotti V; Chiaravalli AM; Carnevali I; Morabito A; Bertario L; Vitellaro M
Tumori; 2019 Feb; 105(1):76-83. PubMed ID: 30117378
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
15. BRAF
Grillo F; Paudice M; Pigozzi S; Dono M; Lastraioli S; Lugaresi M; Bozzano S; Tognoni C; Ali M; Sciallero S; Puccini A; Fassan M; Mastracci L
Histopathology; 2024 Apr; 84(5):877-887. PubMed ID: 38173291
[TBL] [Abstract][Full Text] [Related]
16. Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression.
Lee-Kong SA; Markowitz AJ; Glogowski E; Papadopoulos C; Stadler Z; Weiser MR; Temple LK; Guillem JG
Clin Colorectal Cancer; 2010 Oct; 9(4):255-9. PubMed ID: 20920999
[TBL] [Abstract][Full Text] [Related]
17. Evaluating utility and feasibility of mismatch repair testing of colorectal cancer patients in a low-middle-income country.
Elsayed I; Geraghty R; Mekki SO; Mohamedani AA; Ahern S; Salim OEH; Khalil BBM; Abdelrahim S; Suliman SH; Elhassan MMA; Salah SO; Salih ME; Widatalla AH; Abdelhamed OS; Wang X; Ryan ÉJ; Winter D; Bakhiet S; Sheahan K
Sci Rep; 2022 Jun; 12(1):10998. PubMed ID: 35768447
[TBL] [Abstract][Full Text] [Related]
18. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
[TBL] [Abstract][Full Text] [Related]
19. Loss of INI1 expression in colorectal carcinoma is associated with high tumor grade, poor survival, BRAFV600E mutation, and mismatch repair deficiency.
Wang J; Andrici J; Sioson L; Clarkson A; Sheen A; Farzin M; Toon CW; Turchini J; Gill AJ
Hum Pathol; 2016 Sep; 55():83-90. PubMed ID: 27184481
[TBL] [Abstract][Full Text] [Related]
20. Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection.
Steinhagen E; Shia J; Markowitz AJ; Stadler ZK; Salo-Mullen EE; Zheng J; Lee-Kong SA; Nash GM; Offit K; Guillem JG
J Am Coll Surg; 2012 Jan; 214(1):61-7. PubMed ID: 22192923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
